(VIANEWS) – Shares of PHARMING GROUP (AEX-Index: PHARM.AS) fell by a staggering 20.2% in 10 sessions from €1.2 to €0.96 at 14:08 EST on Thursday, after three sequential sessions in a row of losses. AEX-Index is dropping 0.32% to €757.76, following the last session’s downward trend.
About PHARMING GROUP
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Earnings Per Share
As for profitability, PHARMING GROUP has a trailing twelve months EPS of €0.02.
PE Ratio
PHARMING GROUP has a trailing twelve months price to earnings ratio of 47.93. Meaning, the purchaser of the share is investing €47.93 for every euro of annual earnings.
Volume
Today’s last reported volume for PHARMING GROUP is 2825991 which is 83% below its average volume of 10326500.
More news about PHARMING GROUP (PHARM.AS).
